# Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss

> **NCT01649869** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 54 (actual)

## Conditions studied

- Cytomegalovirus Infection

## Interventions

- **OTHER:** Placebo
- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT01649869
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-24
- **Primary completion:** 2019-12-24
- **Final completion:** 2019-12-24
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01649869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01649869, "Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01649869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*